BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

...from innate immune signaling proteins such as phagocytic receptors including Fc receptors, pattern recognition receptors, RIG-I...
...UndisclosedTARGETSIFIH1 (MDA5) - Interferon induced with helicase C domain 1pp65 (UL83) – Human cytomegalovirus (CMV) phosphoprotein 65RIG-I (DDX58...
BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

...new class of therapeutic oligonucleotides -- stem loop RNAs (SLR) -- that can activate the RIG-I...
...and poorly immunogenic tumors, including melanoma and colon cancer tumor and metastasis models. Activation of RIG-I...
...efficacy. Targets IFNγ - Interferon gamma PD-1 (PDCD1; CD279) - Programmed cell death 1 RIG-1 (DDX58...
BioCentury | Dec 27, 2019
Clinical News

Spring Bank’s HBV therapy on hold after signs of liver damage

...and enrollment of all clinical studies of the small molecule-nucleic acid hybrid that agonizes RIG-I. RIG-I...
...the RIG-I agonist was well tolerated with no systemic interferon-life effects. The immunostimulatory functions of RIG-I...
...RIG-I (DDX58) - DEAD box polypeptide 58 Sandi Wong, Staff Writer Inarigivir soproxil (sb 9200) Spring Bank Pharmaceuticals Inc. DEAD box polypeptide 58 (RIG-I) (DDX58)...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...targets, two immune proteins better know for their therapeutic potential now show promise as biomarkers. RIG-I...
...combinations of RIG-I activators with CTLA-4 inhibitors, according to ClinicalTrials.gov. The most advanced program targeting RIG-I...
...PDCD1; CD279) - Programmed cell death 1 RFC5 - Replication factor C subunit 5 RIG-I (DDX58...
BioCentury | Jul 31, 2019
Finance

How Wellington closed its largest fund yet at €210M

Takeouts of portfolio companies Rigontec and Symetis, coupled with a focus on biotechs in Germany, Austria and Switzerland, helped Wellington Partners raise its largest fund to date. Wellington announced Wednesday the close of Wellington Partners...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...its Phase II ACHIEVE trial of Inarigivir soproxil, a small molecule nucleic acid hybrid targeting RIG-I...
...domain family member 15 PDGFRA (PDGFR2; CD140A) - Platelet derived growth factor receptor A RIG-I (DDX58...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Bank’s Inarigivir soproxil, a small molecule nucleic acid hybrid targeting DEAD box polypeptide 58 (RIG-I; DDX58...
BioCentury | Aug 10, 2018
Clinical News

Spring Bank details peak HBV DNA and HBV RNA reductions for 100 mg dose of inarigivir

...2019. Inarigivir is a small molecule nucleic acid hybrid targeting DEAD box polypeptide 58 (RIG-I; DDX58...
...NASDAQ:SBPH), Hopkinton, Mass. Product: Inarigivir soproxil Business: Infectious Molecular target: DEAD box polypeptide 58 (RIG-I; DDX58...
...caspase recruitment domain family member 15 (NOD2; CARD15) Description: Small molecule nucleic acid hybrid targeting RIG-I...
BioCentury | Aug 7, 2018
Company News

Icahn urges Cigna shareholders to oppose Express Scripts deal

Activist investor Carl Icahn sent a letter Tuesday urging shareholders of Cigna Corp. (NYSE:CI) to vote down its proposed acquisition of Express Scripts Holding Co. (NASDAQ:ESRX). Affiliates of Icahn own about 0.56% of Cigna's outstanding...
BioCentury | Apr 3, 2018
Targets & Mechanisms

Sensor sensibility

...recently by Lewis Cantley’s group. BC: You’ve also discovered the protein MAVS, an adaptor for RIG-I...
...that front, and recently there was a company that targeted the RIG-I pathway, that developed RIG-I...
...cGAMP - cyclic GMP-AMP cGAS - cGAMP synthase MAVS - Mitochondrial antiviral signaling protein RIG-I (DDX58...
Items per page:
1 - 10 of 100